Forde PM - Search Results

1

Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.

Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, Rhymee L, Pereira G, Rao N, Weksler B, Bahary N, Phallen J, Leal A, Bartlett DL, Marrone KA, Naidoo J, Goel A, Levy B, Rosner S, Hann CL, Scott SC, Feliciano J, Lam VK, Ettinger DS, Li QK, Illei PB, Monkhorst K, Scharpf RB, Brahmer JR, Velculescu VE, Zaidi AH, Forde PM, Anagnostou V. Murray JC, et al. Among authors: forde pm. Clin Cancer Res. 2024 Jan 17;30(2):389-403. doi: 10.1158/1078-0432.CCR-23-1469. Clin Cancer Res. 2024. PMID: 37939140 Free PMC article.

2

Targeted therapy for non-small-cell lung cancer: past, present and future.

Forde PM, Ettinger DS. Forde PM, et al. Expert Rev Anticancer Ther. 2013 Jun;13(6):745-58. doi: 10.1586/era.13.47. Expert Rev Anticancer Ther. 2013. PMID: 23773106 Free PMC article. Review.

3

Tumor lysis syndrome in limited-stage small-cell lung cancer.

Boikos SA, Forde PM, Chatterjee S, Hann CL. Boikos SA, et al. Among authors: forde pm. J Thorac Oncol. 2013 Jul;8(7):e61-2. doi: 10.1097/JTO.0b013e318286bb3b. J Thorac Oncol. 2013. PMID: 23774387 Free article. No abstract available.

4

What lies within: novel strategies in immunotherapy for non-small cell lung cancer.

Forde PM, Reiss KA, Zeidan AM, Brahmer JR. Forde PM, et al. Oncologist. 2013;18(11):1203-13. doi: 10.1634/theoncologist.2013-0171. Epub 2013 Oct 8. Oncologist. 2013. PMID: 24105749 Free PMC article. Review.

5

New strategies in lung cancer: translating immunotherapy into clinical practice.

Forde PM, Kelly RJ, Brahmer JR. Forde PM, et al. Clin Cancer Res. 2014 Mar 1;20(5):1067-73. doi: 10.1158/1078-0432.CCR-13-0731. Epub 2014 Jan 27. Clin Cancer Res. 2014. PMID: 24470514 Review.

6

Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.

Forde PM, Hooker CM, Boikos SA, Petrini I, Giaccone G, Rudin CM, Yang SC, Illei PB, Hann CL, Ettinger DS, Brahmer JR, Kelly RJ. Forde PM, et al. J Thorac Oncol. 2014 Mar;9(3):414-8. doi: 10.1097/JTO.0000000000000065. J Thorac Oncol. 2014. PMID: 24518093 Free PMC article.

7

New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer.

Forde PM, Brahmer JR, Kelly RJ. Forde PM, et al. Clin Cancer Res. 2014 May 1;20(9):2244-8. doi: 10.1158/1078-0432.CCR-13-2088. Epub 2014 Mar 18. Clin Cancer Res. 2014. PMID: 24644000 Free PMC article. Review.

8

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Reiss KA, Forde PM, Brahmer JR. Reiss KA, et al. Among authors: forde pm. Immunotherapy. 2014;6(4):459-75. doi: 10.2217/imt.14.9. Immunotherapy. 2014. PMID: 24815784 Free PMC article. Review.

9

Managing acquired resistance in EGFR-mutated non-small cell lung cancer.

Forde PM, Ettinger DS. Forde PM, et al. Clin Adv Hematol Oncol. 2015 Aug;13(8):528-32. Clin Adv Hematol Oncol. 2015. PMID: 26351816 Review.

10

Nivolumab for refractory metastatic squamous non-small-cell lung cancer: fulfilling an unmet need.

Marrone KA, Forde PM. Marrone KA, et al. Among authors: forde pm. Transl Lung Cancer Res. 2015 Dec;4(6):801-3. doi: 10.3978/j.issn.2218-6751.2015.05.04. Transl Lung Cancer Res. 2015. PMID: 26798591 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

142 results

Search Page